Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

Phuong-Thu T Pham; Phuong-Chi T Pham

doi:10.3389/fneph.2022.1014241

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

Front Nephrol. 2022 Nov 10:2:1014241. doi: 10.3389/fneph.2022.1014241. eCollection 2022.

Authors

Phuong-Thu T Pham¹, Phuong-Chi T Pham^{2

3}

Affiliations

¹ Nephrology Division, Kidney Transplant Program David Geffen School of Medicine at University of California at Los Angeles (UCLA), Los Angeles, CA, United States.
² Division of Nephrology and Hypertension Olive-View University of California at Los Angeles (UCLA) Medical Center, Sylmar, CA, United States.
³ David Geffen School of Medicine at University of California at Los Angeles (UCLA), Los Angeles, CA, United States.

Abstract

Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors' opinion on its optimal use in this patient population.

Keywords: PTDM; SGLT2 inhibitor; diabetic kidney disease; diabetic kidney transplant recipients; kidney transplantation; post-transplantation diabetes mellitus; sodium-glucose cotransporter 2 inhibitor.

Publication types

Review